Cargando…
Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current Aspects
In the last decade immunotherapies such as immune checkpoint blockade (ICB) against the PD-1/PD-L1 system have revolutionised the treatment of numerous entities. To date, ovarian cancer has benefited very little from this success story. Possible causes include a rather low mutational burden compared...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494520/ https://www.ncbi.nlm.nih.gov/pubmed/34629492 http://dx.doi.org/10.1055/a-1475-4335 |